This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AV201, AAV-AADC, AAV-DDC, rAAV-hAADC, SAR404477
Description: AV201 is designed to restore and extend the therapeutic effectiveness of levodopa, a precursor to dopamine. AV201 is an AAV vector containing the gene for AADC which is delivered directly to the striatum, the part of the brain that requires dopamine to control movement. Patients with advanced Parkinson's disease receiving AV201 are expected to respond more readily to levodopa as the enhanced AADC expression will improve dopamine generation at the site of action.
Deal Structure: In December 2005, Genzyme purchased Avigen's AAV gene therapy patents for $12 million in cash, plus potential milestone and royalty payments later. This direct purchase of Avigen's assets by Genzyme is not a collaboration, as Avigen will no longer be working in gene therapy.
In June 2009, MediciNova and Avigen announced an agreement for a proposed acquisition of Avigen by MediciNova. In December 2009, the acquisition was completed.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Partners: MediciNova, Inc.
Additional information available to subscribers only: